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Introduction: The incidence of cardiac implantable electronic device (CIED) related infections has risen rapidly since 2004. The minocycline and 
rifampin impregnated AIGIS Rx® antibacterial envelope (TYRX pharmaceuticals, Monmouth, New Jersey) has been associated with a low CIED 
infection rate in a recent retrospective cohort study. Patient-specific and procedural risk factors have been identified for CIED infections. We 
performed a retrospective cohort study at our institution analyzing CIED infection rates in patients receiving an AIGIS Rx® envelope from March 1, 
2009, to August 31, 2011.
Methods: Over the 20 month study period, criteria for use of the AIGIS Rx® envelope included the presence of ≥2 of the following: diabetes, renal 
insufficiency (creatinine ≥1.5mg/dL), systemic anti-coagulation, chronic corticosteroid use, fever ≥100.5 F or leukocytosis ≥11,000 WBC/μL at the 
time of implantation, prior CIED infection, ≥3 leads (CRT systems or abandoned leads), pacemaker dependence, or pocket re-entry within 48 hours. 
CIED infection rate at 90 days was compared to a cohort of 671 patients with matched risk factors and a CIED implanted during the 18 month 
period prior to use of the AIGIS Rx® envelope at our institution.
Results: 209 AIGIS Rx® envelopes were implanted during the study period. The mean number of CIED infection risk factors was 2.8±1.2. Two or 
more risk factors were present in 88% of patients. Average age was 66.9 years and 69% were male. The most frequent risk factors included ≥3 leads 
(CRT systems or abandoned leads) in 132, systemic anti-coagulation in 117, diabetes in 90, and renal insufficiency in 76. Forty patients had fever or 
leukocytosis within 24 hours of implant. The control cohort (N=671) was matched for CIED infection risk factors (mean 2.7±0.9). After a minimum of 
90 days of follow-up, there were no CIED infections in patients who received AIGIS Rx® implants, compared to 15 in the control group (0% vs. 2.2%, 
p=0.02).
Conclusions: In patients at high-risk for CIED infection, implantation of the AIGIS Rx® antibiotic envelope during CIED implantation at our 
institution was associated with a marked reduction in CIED infections compared to a matched control cohort.
